Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events in T2DM + ASCVD; signal for SGLT2i in HF and CKD.
CANVAS - Canagliflozin lowered CV events in T2DM + ASCVD or ASCVD risk; signal for SGLT2i in HF and CKD.
DECLARE-TIMI 58 - Dapagliflozin lowered CV death or HHF, but had no effect on MACE, in T2DM + ASCVD or ASCVD risk.
CREDENCE - Canagliflozin lowered adverse kidney events in CKD + T2DM; first renal outcomes trial in SGLT2i.
DAPA-CKD - Dapagliflozin lowered adverse kidney events for patients with CKD, with or without T2DM.
DAPA-HF - Dapagliflozin improved HF outcomes in HFrEF on GDMT, with or without T2DM.
EMPEROR-REDUCED - Empagliflozin improved HF outcomes in HFrEF on GDMT, with or without T2DM.

by Dr. Jefferson Triozzi @nepherson and Dr. Tony McClafferty @mcclaffertyMD

#SGLT2 #inhibitors #EBM #trial #visualabstract #table #CVD #CKD